Vanda Pharmaceuticals Inc. Daily Stock Analysis

Daily Stock Analysis, VNDA, Vanda Pharmaceuticals Inc, priceseries

Vanda Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
10.91
Close
11.08
High
11.30
Low
10.74
Previous Close
10.84
Daily Price Gain
0.24
YTD High
16.93
YTD High Date
Jan 5, 2022
YTD Low
10.60
YTD Low Date
Feb 24, 2022
YTD Price Change
-5.47
YTD Gain
-33.05%
52 Week High
21.86
52 Week High Date
Jul 1, 2021
52 Week Low
10.60
52 Week Low Date
Feb 24, 2022
52 Week Price Change
-6.86
52 Week Gain
-38.24%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 19. 2017
14.05
Jul 17. 2017
16.53
19 Trading Days
17.65%
Link
LONG
Aug 24. 2017
16.15
Sep 13. 2017
17.10
13 Trading Days
5.88%
Link
LONG
Jan 22. 2018
15.10
Jan 31. 2018
15.94
7 Trading Days
5.57%
Link
LONG
Feb 16. 2018
17.10
Mar 15. 2018
19.20
18 Trading Days
12.30%
Link
LONG
May 7. 2018
15.70
May 21. 2018
16.56
10 Trading Days
5.47%
Link
LONG
Sep 18. 2018
19.45
Oct 10. 2018
21.96
16 Trading Days
12.92%
Link
LONG
Nov 28. 2018
24.05
Dec 11. 2018
27.31
8 Trading Days
13.55%
Link
LONG
Nov 7. 2019
14.53
Dec 11. 2019
16.73
23 Trading Days
15.13%
Link
LONG
Mar 30. 2020
9.67
Apr 1. 2020
10.17
2 Trading Days
5.17%
Link
LONG
Sep 30. 2020
9.66
Oct 19. 2020
10.49
13 Trading Days
8.60%
Link
LONG
Nov 2. 2020
10.96
Nov 19. 2020
12.46
13 Trading Days
13.71%
Link
Company Information
Stock Symbol
VNDA
Exchange
NasdaqGM
Company URL
http://www.vandapharma.com
Company Phone
202-734-3400
CEO
Mihael Hristos Polymeropoulos
Headquarters
District Of Columbia
Business Address
2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON, DC 20037
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001347178
About

Vanda Pharmaceuticals, Inc. engages in the research, development, and commercialization of biopharmaceutical products. It intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt and Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Description

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt (iloperidone), a product for the treatment of schizophrenia. Its clinical development products include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; Trichostatin A, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. The company markets its products in the United States, Canada, Europe Union, Israel, and Mexico. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading